Anti-C5 Antibody Dosing for Pediatric PNH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients are limited, and there is a need for effective methods to manage the disease's debilitating symptoms and complications such as hemolysis, thrombosis, and bone marrow failure.
Innovation Solution
Administration of anti-C5 antibodies, specifically ravulizumab or its antigen binding fragments, following a particular clinical dosage regimen to inhibit complement-mediated hemolysis, which includes specific dosing schedules and weight-based dosing to achieve effective serum trough concentrations and reduce hemolysis-related parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for pediatric PNH patients, then the treatment options are limited, but the disease symptoms and complications (hemolysis, thrombosis, bone marrow failure) cannot be effectively managed
Solution Approach 1:
The patent applies parameter changes by establishing specific dosage regimens (loading dose of 600-900 mg followed by maintenance doses of 300-600 mg every 4-8 weeks) and weight-based dosing strategies to optimize the effectiveness of anti-C5 antibodies in pediatric patients. This resolves the contradiction by providing reliable treatment through precisely controlled dosing parameters while maintaining adaptability to different patient weights and ages.
2Reliability
If anti-C5 antibodies are administered without specific dosage regimens, then treatment flexibility is maintained, but effective serum trough concentrations cannot be achieved to prevent breakthrough hemolysis
Solution Approach 1:
The patent applies preliminary action by administering a loading dose of 600-900 mg before maintenance doses to rapidly achieve effective serum trough concentrations. This preliminary action ensures reliable prevention of breakthrough hemolysis from the start of treatment, while the structured maintenance schedule simplifies long-term management despite the initial complexity.
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring serum trough concentrations and adjusting maintenance dosing intervals (every 4-8 weeks) and doses (300-600 mg) based on individual patient response and weight. This feedback loop maintains reliable hemolysis prevention while adapting the dosing complexity to each patient's needs.
3Reliability
If higher doses of anti-C5 antibodies are administered, then hemolysis control is improved, but the risk of adverse effects and treatment burden increases
Solution Approach 1:
The patent applies parameter changes by establishing optimized dosage ranges (loading dose of 600-900 mg, maintenance doses of 300-600 mg) and dosing intervals (every 4-8 weeks) based on patient weight and response. This resolves the contradiction by achieving reliable hemolysis control through precisely controlled dosing parameters that minimize adverse effects and treatment burden compared to unoptimized higher doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment significantly reduces lactate dehydrogenase levels, prevents breakthrough hemolysis, stabilizes hemoglobin, and improves quality of life by effectively inhibiting complement activation, thereby alleviating the symptoms and complications of PNH in pediatric patients.
Implementation Method 1
Administration of anti-C5 antibodies, specifically ravulizumab or its antigen binding fragments, following a particular clinical dosage regimen to inhibit complement-mediated hemolysis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.